Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statement Detail

v3.22.1
Condensed Consolidated Financial Statement Detail
3 Months Ended
Mar. 31, 2022
Condensed Consolidated Financial Statement Detail  
Condensed Consolidated Financial Statement Detail

3. Condensed Consolidated Financial Statements Details

Equity Securities

As of March 31, 2022 and December 31, 2021, equity securities consisted of an investment in Rezolute’s common stock of $0.5 million and $0.8 million, respectively (Note 4). For the three months ended March 31, 2022 and 2021, the Company recognized a loss of $0.2 million and $0.7 million, respectively, due to the change in fair value of its investment in Rezolute’s common stock in the other (expense) income, net line item of the condensed consolidated statements of operations and comprehensive loss.

Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):

March 31, 

December 31, 

    

2022

    

2021

Accrued legal and accounting fees

445

295

Accrued incentive compensation

231

55

Accrued payroll and benefits

 

129

 

135

Other accrued liabilities

50

40

Total

$

855

$

525

Net Loss Per Share Attributable to Common Stockholders

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):

Three Months Ended March 31, 

    

2022

    

2021

Numerator

 

  

 

  

Net loss

$

(2,280)

$

(7,373)

Less: Series A accumulated dividends

 

(530)

 

(530)

Less: Series B accumulated dividends

(838)

Net loss available to common stockholders, basic and diluted

$

(3,648)

$

(7,903)

 

Denominator

 

 

Weighted average shares used in computing basic and diluted net loss per share available to common stockholders

 

11,330

 

11,240

Basic and diluted net loss per share available to common stockholders

$

(0.32)

$

(0.70)

Potentially dilutive securities are excluded from the calculation of diluted net loss per share available to common stockholders if their inclusion is anti-dilutive.

The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):

Three Months Ended March 31, 

    

2022

    

2021

Convertible preferred stock

5,003

5,003

Common stock options

 

697

277

Warrants for common stock

 

6

5

Total

 

5,706

 

5,285